OncoMatch/Clinical Trials/NCT06714604
Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC
Is NCT06714604 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including FOLFIRINOX or gemcitabine-nab-paclitaxel and FOLFIRINOX or gemcitabine-nab-paclitaxel for locally advanced pancreatic adenocarcinoma.
Treatment: FOLFIRINOX or gemcitabine-nab-paclitaxel · FOLFIRINOX or gemcitabine-nab-paclitaxel — The goal of this multicenter randomized controlled phase III trial is to compare two durations of neoadjuvant chemotherapy (NAT) with mFOLFIRINOX or gemcitabine-nab-paclitaxel (GnP) before attempt for surgical resection in patients with borderline (BR) and locally advanced pancreatic cancer (LAPC). Patients with histologically confirmed non-metastatic BR/LAPC evaluated to potentially tolerate any of the treatment regimens and pancreatic surgery will be randomized to receive either standard duration NAT with 6 cycles mFOLFIRINOX or 4 cycles GnP or prolonged duration NAT with either 12 cycles mFOLFIRINOX or 6 cycles GnP before attempt for surgical resection, provided there is no evidence of disease progression. The primary objective is to compare the overall survival at 24 months after randomization of all treated patients and among the resected patients with BR/LAPC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: oncologic treatment
previous oncologic treatment for PC within the past 5 years
Lab requirements
Blood counts
Granulocyte count < 1500 per cubic millimetre (< 1,5 x 10^9/L); Platelet count < 100 000 per cubic millimetre (< 100 x 10^9/L); Albumin <2,5 g/dl (<25 g/L)
Kidney function
Serum creatinine > 1.5 UNL (upper limit normal range)
Liver function
Total bilirubin >3 x ULN; ASAT (SGOT) and ALAT (SGPT) >2.5 x institutional ULN
Granulocyte count < 1500 per cubic millimetre (< 1,5 x 10^9/L); Platelet count < 100 000 per cubic millimetre (< 100 x 10^9/L); Serum creatinine > 1.5 UNL (upper limit normal range); Albumin <2,5 g/dl (<25 g/L); Total bilirubin >3 x ULN; ASAT (SGOT) and ALAT (SGPT) >2.5 x institutional ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify